跳至主要内容
临床试验/CTIS2023-504553-12-01
CTIS2023-504553-12-01招募中1 期

Aspirin to prevent cardiovascular events in patients with community-acquired pneumonia

Amsterdam UMC0 个研究点目标入组 760 人开始时间: 2023年7月6日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
760

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 65+(—)
性别
All

入选标准

  • 40 years or older, Community-acquired pneumonia, defined as clinical signs of pneumonia, and radiological evidence of a new infiltrate consistent with pneumonia, Moderate to severe CAP: CURB-65 score 2 or higher, or PSI score 3 or higher, Admitted to hospital

排除标准

  • Conditions which require antiplatelet therapy, Use of vitamin K antagonists, direct oral anticoagulants or therapeutic LMWH, Contraindications for aspirin: recent (<1 month) hemorrhagic CVA, recent major gastro-intestinal bleeding or other hemorrhage, active bleeding, thrombocytopenia < 100, known hemorrhagic diathesis, allergy for salicylates., Uncontrolled hypertension (systolic BP>180 mm Hg or diastolic BP>110 mm Hg), Life expectancy less than one month, Pregnancy or breastfeeding

研究者

发起方
Amsterdam UMC

相似试验